Silviu-Mihail Dumitru

Dr. Silviu-Mihail Dumitru

Bronchoscopy department, National Institute of Pneumology Marius Nasta, Bucharest, Bucureşti, Romania
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
RMRadu Matache
Radu Matache
AAAdelina Ana Afetelor
Adelina Ana Afetelor
AVAncuta Mihaela Voinea
Ancuta Mihaela Voinea
GCGeorge Codrut Cosoveanu
George Codrut Cosoveanu
Silviu-Mihail DumitruSilviu-Mihail Dumitru
Silviu-Mihail Dumitru
CSCornel Savu
Cornel Savu
Background: Mediastinal staging plays a critical role in guiding treatment decisions for non-small cell lung cancer (NSCLC). While mediastinoscopy has been the gold standard for assessing mediastinal lymph node involvement, endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has emerged as a minimally invasive alternative with comparable diagnostic accuracy. This systematic review evaluates the diagnostic performance, safety, cost-effectiveness, and feasibility of EBUS-TBNA versus mediastinoscopy for mediastinal staging. Methods: A systematic literature review was conducted in accordance with PRISMA guidelines, including searches in Medline, Scopus, EMBASE, and Cochrane databases for studies published from 2010 onwards. A total of 1542 studies were identified, and after removing duplicates and applying eligibility criteria, 100 studies were included for detailed analysis. The extracted data focused on sensitivity, specificity, complications, economic impact, and patient outcomes. Results: EBUS-TBNA demonstrated high sensitivity (85–94%) and specificity (~100%), making it an effective first-line modality for NSCLC staging. Mediastinoscopy remained highly specific (~100%) but exhibited slightly lower sensitivity (86–90%). EBUS-TBNA had a lower complication rate (~2%) and was more cost-effective, while mediastinoscopy provided larger biopsy samples, essential for molecular and histological analyses. The need for general anaesthesia, longer hospital stays, and increased procedural costs make mediastinoscopy less favourable as an initial approach. Combining both techniques in select cases enhanced overall staging accuracy, reducing false negatives and improving diagnostic confidence. Conclusions: EBUS-TBNA has become the preferred first-line mediastinal staging method due to its minimally invasive approach, high diagnostic accuracy, and lower cost. However, mediastinoscopy remains crucial in cases requiring posterior mediastinal node assessment or larger tissue samples. The integration of both techniques in a stepwise diagnostic strategy offers the highest accuracy while minimizing risks and costs. Given the lower hospitalization rates and economic benefits associated with EBUS-TBNA, its widespread adoption may contribute to more efficient resource utilization in healthcare systems.

14 July 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
ILIustina Leonte
Iustina Leonte
KIKarina Ivanov
Karina Ivanov
MȘMarghescu Angela Ștefania
Marghescu Angela Ștefania
RMRadu Matache
Radu Matache
VNValeria Florica Negru
Valeria Florica Negru
Beatrice MahlerBeatrice Mahler
Beatrice Mahler
We present the case of a 35-year-old patient without pathological history who developed hemopneumothorax due to altitude barotrauma during a commercial airline flight. The computed tomography (CT) of the chest identified the presence of right hydropneumothorax and emphysema “blebs” and bubbles. After the therapeutic insertion of a drain tube, the patient returned to the country by land transport. Three weeks later, he was diagnosed with right-sided pleurisy based on a CT scan with contrast material. A surgical intervention was then performed, and three biopsy samples were taken; the histopathological result highlighted suggestive elements for the diagnosis of desquamative interstitial pneumonia (DIP).

1 January 2019 in Health and Primary Care
Verified
Journal Article
Open access
Silviu-Mihail DumitruSilviu-Mihail Dumitru
Silviu-Mihail Dumitru
ADAntonela Dragomir
Antonela Dragomir
FMFlorin Dumitru Mihaltan
Florin Dumitru Mihaltan

5 September 2021 in European Respiratory Journal
Verified
Conference Paper
Closed access
DZDragos-Cosmin Zaharia
Dragos-Cosmin Zaharia
ACAlexandra-Maria Cristea
Alexandra-Maria Cristea
ADAntonela Dragomir
Antonela Dragomir
EIElmira Ibraim
Elmira Ibraim
GCGina-Ana Ciolan
Gina-Ana Ciolan
ISIrina Strambu
Irina Strambu
Background: One of the most common comorbidities in the SARS-COV2 infection is Diabetes Mellitus (DM), either previously diagnosed or as a result of SARS-Cov2 aggression on ß-pancreatic cells (Yang, J.et.al, 2020). A higher mortality was seen in SARS-COV 2 with DM. Hyperglycemia (HG) was shown to be a risk factor of deaths in these patients. Diabetes mellitus (DM) and hyperglycemia (HG) were studied as risk factors for severity and mortality in SARS-Cov2 positive patients using the Chi-square test of independence with SPSS. Results: 602 RT-PCR SARS-Cov2 positive cases were analyzed. 115 (19,1%) had known type II DM and 73 (63,48%) of them had HG on admission (>126 mg/dL). Of the 487 non-DM patients, 48 (9,86%) had HG. 24 (20,87%) of the 115 patients with DM had died and 11 (22,92%) of the 48 non-DM patients with HG had died. An association between DM and mortality was found ((X2(1) = 32.500, p>0.001). Using a layer of severity an association was found between DM and deaths only in severe cases (X2(1) = 4.530, p=0.033). Regarding HG, there is an association with death overall ((X2(2) = 59.689, P>0.001) confirmed only in severe cases ((X2(2) = 17.217, p<0.001). When using a layer of known DM or not, an association was found between HG and death only in non-diabetic patients (X2 (2) = 35.310, p<0.001) while HG in DM patients does not associate with death (X2(2) = 2,895, p=0.235). Conclusion: There is a clear association between DM and death in severe SARS-Cov2 infections. Furthermore, among our 602 positive patients, HG on admission seems to be an overall mortality risk factor but when looking at known DM vs not-known DM patients, HG associates with mortality only in not-known DM patients.

5 September 2021 in European Respiratory Journal
Verified
Conference Paper
Closed access
DZDragos-Cosmin Zaharia
Dragos-Cosmin Zaharia
AMAlexandru Muntean
Alexandru Muntean
ACAlexandra-Maria Cristea
Alexandra-Maria Cristea
ADAntonela Dragomir
Antonela Dragomir
EIElmira Ibraim
Elmira Ibraim
ISIrina Strambu
Irina Strambu
Background: Romania has entered the pandemic fight in 26 February 2020 when the first positive case was identified (Inst. Cantacuzino, 27-feb-2020). Even from the beginning, in the first 6 months of pandemic, Marius Nasta Pneumology Institute received mostly moderate and severe covid-19 pneumonia patients. Results: A total of 602 SARS-Cov2 RT-PCR positive patients’ cases were analyzed. Among those patients, 46 (7,64%) were asymptomatic, 210 (34,88%) had mild, 168 (27,91%) had moderate and 178 (29,57%) had severe covid-19 disease. 226 (37,54%) patients had no known comorbidities, 227 (37,7%) had systemic hypertension, 118 (19,6%) had obesity, 115 (19,10%) had dibetes mellitus and 48 (7,97%) had a newly revealed hyperglycaemia, 106 (17,6%) had cardiac pathology and 50 patients (8,3%) had respiratory pathology. Among these patients, 143 (23,7%) had one comorbidity, 126 (20,93%) had two, 72 (11,96%) had three, 25 (4,15%) had four and 8 (1,32%) had 5 comorbidities. A binomial Generalized Linear Model (GLM) was built using R statistical software. Among clinical and laboratory factors which were evaluated, age (p=0.021), number of comorbidities (p/,0.001), and D-dimer (p<0.01), C reactive protein (p=0.038) and feritin levels (p<0.01) on the day of hospitalization were significantly associated with patient mortality. Conclusion: Increased age, number of comorbidities and cytokine-storm biomarkers levels were associated with mortality. A bioclinical score of risk could be computed to estimate the covid-19 disease prognosis and assign different classes of prognoses with optimal treatment to decrease mortality.

1 October 2021 in Pneumologia
Verified
Journal Article
Open access
PDF file
JDJustina Antonela Dragomir
Justina Antonela Dragomir
Silviu-Mihail DumitruSilviu-Mihail Dumitru
Silviu-Mihail Dumitru
Tuberculosis (TB) is an infectious and contagious disease caused by Mycobacterium tuberculosis, and it mainly affects the lungs. As Romania has consistently ranked first in the European Union (EU) in terms of the incidence and prevalence of TB in the past years, this paper aims to bring to the attention of physicians the new therapeutic regimens and ways to approach patients with multidrug resistant TB and extended resistance.